CLAIMS

1. A peptide consisting of the amino acid sequence of SEQ ID No. 39, or a pharmaceutically acceptable salt thereof.

2. The peptide according to Claim 1, wherein said peptide is a part of a fusion protein, in particular fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii), or is fused to an antibody.

3. The peptide according to Claim 1, wherein said peptide includes non-peptide bonds.

4. An isolated binding agent that binds, and preferably binds specifically, to:
(i) the peptide according to Claim 1 or Claim 3; or
(ii) the amino acid sequence of SEQ ID No. 39 of the peptide according to Claim 2,
wherein said isolated binding agent is an antibody or fragment thereof, or a TCR or an sTCR or fragment thereof.

5 An isolated T-cell receptor reactive with the peptide according to any one of Claims 1 to 3.

6. An *in vitro* method for producing an activated cytotoxic T lymphocyte (CTL), the method comprising contacting *in vitro* a CTL with antigen-loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is the peptide according to Claim 1.

7. The method according to Claim 6, wherein said antigen is loaded onto class I MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of said antigen with said antigen-presenting cell.

8. The method according to Claim 6 or Claim 7, wherein said antigen-presenting cell comprises an expression vector capable of expressing the peptide according to Claim 1.

9. An activated cytotoxic T lymphocyte (CTL), produced by the method according to any one of Claims 6 to 8, wherein said CTL selectively recognises a cell which aberrantly expresses a peptide comprising an amino acid sequence as given in Claim 1.

10. An *in vitro* method for producing a TCR or sTCR, or a fragment thereof, that is specific for the peptide according to any one of Claims 1 to 3, the method comprising cloning of variable domains from an activated cytotoxic T lymphocyte (CTL) according to Claim 9, and expressing said TCR or sTCR, or fragment thereof, in a suitable host and/or expression system.

11. A host cell comprising a nucleic acid encoding the peptide according to Claim 1, or the isolated binding agent according to Claim 4, or the isolated T-cell receptor according to Claim 5, or an expression vector expressing said nucleic acid, wherein said host cell is not a cell within a human, or a human embryonic stem cell.

12. The host cell according to Claim 11, wherein said cell is an antigen presenting cell, such as a dendritic cell.

13. A method for producing the peptide according to Claim 1, the method comprising culturing the host cell according to Claim 11 or Claim 12, and isolating said peptide from the host cell or its culture medium.

14. A pharmaceutical composition comprising the peptide according to any one of Claims 1 to 3, the isolated binding agent according to Claim 4, the isolated T-cell receptor according to Claim 5, the activated cytotoxic T lymphocyte according to Claim 9, or the host cell according to Claim 11 or Claim 12, and at least one other component selected from the group consisting of pharmaceutically acceptable, preferably aqueous, carriers and/or excipients, such as buffers, binding agents, blasting agents, diluents, flavours, lubricants, and immune stimulating or immune modulating substances, such as cytokines, immuno-modulators, adjuvants and therapeutic substances with immune modulating properties.

15. The pharmaceutical composition according to claim 14, wherein (i) the pharmaceutical composition further comprises an adjuvant, and/or (ii) wherein the pharmaceutical composition is a vaccine or a cellular therapeutic agent.

16. The pharmaceutical composition according to claim 15, wherein the adjuvant is an in-terleukin, including IL-2, IL-15 or a combination thereof.

17. Use of the peptide according to any one of Claims 1 to 3, the isolated binding agent according to Claim 4, the isolated T-cell receptor according to Claim 5, the activated cytotoxic T lymphocyte according to Claim 9, or the host cell according to Claim 11 or Claim 12, for the preparation of a medicament for the prevention or treatment of cancer, wherein said cancer is associated with LAMC2 expression.

18, The use according to Claim 17, wherein said medicament is a vaccine.

19. The use according to Claim 17 or Claim 18, wherein said cancer is selected from non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma.

20. The use according to any one of Claims 17, 18 and 19, wherein the prevention or treatment of cancer includes adoptive cellular therapy.

21. An autologous or allogeneic human cytotoxic T cell (CTL), excluding a cell within a human body, recombinantly transfected with an isolated binding agent according to Claim 4 or a T-cell receptor to Claim 5.